Prolonged response without prolonged chemotherapy: A lesson from PCV chemotherapy in low-grade gliomas

Neuro-Oncology

Volumn 12, Issue 10, 2010, Pages 1078-1082

  Peyre, Matthieu ^a   Cartalat Carel, Stéphanie ^a   Meyronet, David ^a,b,c   Ricard, Damien ^d   Jouvet, Anne ^a,b,c   Pallud, Johan ^e   Mokhtari, Karima ^f   Guyotat, Jacques ^a   Jouanneau, Emmanuel ^a,b,c   Sunyach, Marie Pierre ^g   Frappaz, Didier ^g   Honnorat, Jérôme ^a,b,c   Ducray, François ^a,b,c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d University of Paris Descartes   (France)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

Growth kinetics; Low grade glioma; PCV chemotherapy

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT RESPONSE;

EID: 78650136376     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq055     Document Type: Article

References (12)

1. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524-528.
2. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380-383.
3. Mandonnet E, Pallud J, Fontaine D, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33:91-96.
4. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of lowgrade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484-490.
5. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251-255.
6. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14:391-398.
7. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203-207.
8. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of lowgrade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. 2005;103:802-809.
9. Higuchi Y, Iwadate Y, Yamaura A. Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology. 2004;63:2384-2386.
10. Catenoix H, Honnorat J, Cartalat-Carel S, Chapuis F, Nighoghossian N, Trouillas P. Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents. Rev Neurol. 2006;162:1069-1075.
11. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836.
12. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722.